Inflammation and atrophy in multiple sclerosis: MRI associations with disease course.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Neurological Sciences

• Publication date

  2001-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-510X(01)00576-7PMID 11535239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• Randomized controlled trial of interferon-beta-1a in secondary progressive MS

  2001cited by this paper
• Short‐term ventricular volume changes on serial MRI in multiple sclerosis

  2000cited by this paper
• Relapses and progression of disability in multiple sclerosis.

  2000cited by this paper
• Progressive cerebral atrophy in MS

  2000cited by this paper
• A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis

  2000cited by this paper
• The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

  2000cited by this paper
• Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

  1999cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

  1999cited by this paper
• Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

  1999cited by this paper
• Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis.

  1999cited by this paper
• A longitudinal study of brain atrophy in relapsing multiple sclerosis

  1999cited by this paper
• From enhancing lesions to brain atrophy in relapsing MS.

  1999cited by this paper
• Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H

  1999cited by this paper
• Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?

  1999cited by this paper
• Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis

  1999cited by this paper
• Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment.

  1999cited by this paper
• Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis.

  1999cited by this paper
• Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.

  1999cited by this paper
• Axonal transection in the lesions of multiple sclerosis.

  1998cited by this paper
• Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

  1998cited by this paper
• Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

  1998cited by this paper
• Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis

  1998cited by this paper
• Spinal cord atrophy and disability in MS

  1998cited by this paper
• Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Axonal damage in acute multiple sclerosis lesions.

  1997cited by this paper
• Automatic analysis of cerebral atrophy.

  1997cited by this paper
• Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression.

  1996cited by this paper
• A high‐resolution three‐dimensional T1‐weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis

  1996cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss.

  1995cited by this paper
• Quantitative volumetric analysis of brain MR: normative database spanning 5 decades of life.

  1995cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

  1989cited by this paper
• Cranial and Spinal Magnetic Resonance Imaging: An Atlas and Guide

  1988cited by this paper
• The efficiency of systematic sampling in stereology and its prediction *

  1987cited by this paper
• Statistical methods for assessing agreement between two methods of clinical measurement.

  1986cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• AKUFO AND IBARAPA.

  1965cited by this paper

• Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis

  2022cites this paper
• Origin of orientation‐dependent R1 (=1/T1) relaxation in white matter

  2020cites this paper
• Central nervous system targeted autoimmunity causes regional atrophy: a 9.4T MRI study of the EAE mouse model of Multiple Sclerosis

  2019cites this paper
• Brain Morphometry in Multiple Sclerosis

  2018cites this paper
• The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis

  2017cites this paper
• GLUTATHIONE AS A PREDICTOR OF NEUROPSYCHOLOGICAL IMPAIRMENT IN PATIENTS WITH RELAPSING REMITTING, SECONDARY PROGRESSIVE, AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  2014cites this paper
• Perfusion and Diffusion Abnormalities of Multiple Sclerosis Lesions and Relevance of Classified Lesions to Disease Status

  2014cites this paper
• Segmentation Methods Of Spinal Cord/Spinal Canal To Detect Pathologies

  2014cites this paper
• Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage.

  2013cites this paper
• Personalized Management of Multiple Sclerosis

  2013cites this paper
• Measurement of cerebral atrophy in multiple sclerosis

  2013cites this paper
• Global cerebral atrophy after subarachnoid hemorrhage: a possible marker of acute brain injury and assessment of its impact on outcome.

  2013cites this paper
• Examination of the Relationship Between Average Plaque Volume and Clinical and Demographic Characteristics in Multiple Sclerosis Patients Using a Stereological Method

  2011cites this paper
• Role of MRI in diagnosis and treatment of multiple sclerosis.

  2010cites this paper
• ole of MRI in diagnosis and treatment of multiple sclerosis ohammad

  2010cites this paper
• Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy

  2009cites this paper
• Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study

  2009cites this paper
• Normalized Upper Cervical Spinal Cord Atrophy in Multiple Sclerosis

  2008cites this paper
• Recent Advances in Neuroimaging of Multiple Sclerosis

  2008cites this paper
• Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis

  2007cites this paper
• MRI relapses have significant pathologic and clinical implications in multiple sclerosis.

  2007cites this paper
• Magnetic resonance imaging measures of brain atrophy in multiple sclerosis

  2006cites this paper
• Secondary progressive multiple sclerosis: current knowledge and future challenges.

  2006cites this paper
• Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain

  2006cites this paper
• 14 – Brain Atrophy as a Measure of Neurodegeneration and Neuroprotection

  2005cites this paper
• Role of MRI in multiple sclerosis II: brain and spinal cord atrophy.

  2004cites this paper
• The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis

  2004cites this paper
• Sensitivity and reproducibility of a new fast 3D segmentation technique for clinical MR-based brain volumetry in multiple sclerosis

  2004cites this paper
• Magnetic Resonance Imaging Surrogates of Multiple Sclerosis Pathology and Their Relationship to Central Nervous System Atrophy

  2004cites this paper
• MRI Visualization of Multiple Sclerosis

  2004cites this paper
• The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three‐dimensional MRI study

  2003cites this paper
• Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences.

  2003cites this paper
• Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β-1a (Rebif) treatment trial

  2003cites this paper
• Interventions for the Prevention of Brain Atrophy in Multiple Sclerosis

  2003cites this paper
• Is Gadolinium Enhancement Predictive of the Development of Brain Atrophy in Multiple Sclerosis? A Review of the Literature

  2002cites this paper
• The clinico‐radiological paradox in multiple sclerosis revisited

  2002cites this paper
• A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta

  2002cites this paper
• [Initial axonal lesion in multiple sclerosis. Reasons for early treatment].

  2002cites this paper
• Magnetic Resonance Imaging and Spectroscopy : Insights into the Pathology and Pathophysiology of Multiple Sclerosis .

  2002cites this paper